Oxford Immunotec Limited
91 Milton Park
Abingdon
Oxon
OX14 4RY
United Kingdom
Tel: 44-0-1235-442780
Fax: 44-0-1235-442781
Website: http://www.oxfordimmunotec.com/
Email: info@oxfordimmunotec.com
160 articles about Oxford Immunotec Limited
-
It's been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
-
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T Cell Response to SARS-CoV-2 Infection
5/18/2021
Oxford Immunotec, a global, high-growth diagnostics company part of PerkinElmer , today announced that its T-SPOT ® Discovery SARS-CoV-2 kit is being used for T cell testing in the UK COVID-19 Human Challenge Study, a national collaboration including the UK government, the NHS, academia and the private sector.
-
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
-
Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit
2/8/2021
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea.
-
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
1/14/2021
The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes
-
Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South Korea
12/10/2020
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced that the Company’s T-Cell Select reagent kit has been approved for use by the Ministry of Food and Drug Safety, South Korea. The T-Cell Select reagent kit is an immune cell separation reagent. It is used to automate the preparation of the cells required to run the Company’s T-SPOT. TB test,
-
Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec
11/10/2020
Oxford Immunotec Global PLC, a global, high-growth diagnostics company, announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration between the Company and Public Health England.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
-
UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials
10/22/2020
Oxford Immunotec Global PLC announced that it has been selected to provide T cell testing to the UK Vaccines Taskforce, a body formed by the UK Government to assess the suitability of vaccines for use in the UK population.
-
Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 Test
9/22/2020
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has entered into an extensive research collaboration with Public Health England (PHE), an executive agency of the UK’s Department for Health and Social Care (DHSC). As part of this, PHE has launched the ‘Evaluating Detection of SARS-CoV-2 antibodies using home test kits’ study (EDSAB-HOME
-
Oxford Immunotec Reports Second Quarter 2020 Financial Results
8/4/2020
Oxford Immunotec Global PLC, a global diagnostics company, announced second quarter 2020 financial results.
-
Oxford Immunotec Schedules Second Quarter 2020 Earnings Release and Conference Call for August 4, 2020
7/21/2020
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2020 financial results before the open of the market on Tuesday, August 4, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m
-
Oxford Immunotec Announces Agreement with Stop TB Partnership - Global Drug Facility (GDF) to Provide Access to the T-SPOT®.TB Test for 100+ TB Burden Countries
7/20/2020
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), today announced that it has entered into a long-term agreement to supply its T-SPOT. TB test and associated accessories to the Stop TB Partnership - Global Drug Facility (GDF). This follows the inclusion of the T-SPOT. TB test in the GDF’s diagnostics catalog for the detection of tuberculosis (TB) infection. The GDF is the largest global provider of qu
-
Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19
5/19/2020
Oxford Immunotec Global PLC, a global, high-growth diagnostics company, announces the release of the T-SPOT Discovery SARS-CoV-2 test kit.
-
Oxford Immunotec Reports First Quarter 2020 Financial Results
5/5/2020
First quarter revenue of $13.9 million, a decrease of 6% compared to prior year period, due to the impact of COVID-19 in China
-
Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020
4/29/2020
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on Tuesday, May 5, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m.
-
Oxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020
2/24/2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2019 financial results before the open of the market on Monday, March 2, 2020. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial result
-
Oxford Immunotec Announces New Data on the Utility of T-SPOT®.CMV in Kidney and Stem Cell Transplant
2/20/2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT. CMV ; a test for measuring the strength of a patient’s cellular immune response to Cytomegalovirus (CMV) in kidney and stem cell transplant. Increased response in the T-SPOT. CMV test is associ
-
Oxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the New China Virus
1/23/2020
Oxford Immunotec Global PLC, a global, high-growth diagnostics company, announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the benefits of the T-SPOT®.TB test to mainland China and assist with differentiating tuberculosis from other respiratory infections.
-
Oxford Immunotec to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
The conference will be held at the Westin St. Francis Hotel in San Francisco.